JOURNAL OF HEPATOLOGY If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password PROGRESSIVE CHOLANGIOPATHY IN COVID-19 PATIENTS: OTHER Ketamine, a nonbarbiturate general anaesthetic drug, has been proposed, off-label, as a second-line agent for maintenance sedation of patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, including those with Coronavirus infectious disease 2019 (COVID-19). 1 Cholangiopathy is reported after chronic exposure to ketamine, including in drug users and in burned NON-INVASIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. HEPATOPULMONARY SYNDROME Hepatopulmonary syndrome (HPS) is the most common cause of respiratory insufficiency in patients with chronic liver disease. It is characterised by a gas exchange abnormality caused by intrapulmonary vascular dilatations (IPVD) in patients with liver diseases. It occurs in 5–32% of liver transplant candidates.1 Abnormal oxygenation is defined by elevated alveolar-arterial oxygen gradient CIRCULAR RNA CSMARCA5 INHIBITS GROWTH AND METASTASIS IN Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.1 Although it has long been highly prevalent in Asia and Africa, it was relatively less common in the Western world. However, over the past three decades HCC incidence has doubled in the United Kingdom and tripled in the United States.2,3 Largely because of the propensity for metastasis, the five-year survival rate GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant JOURNAL OF HEPATOLOGY If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password PROGRESSIVE CHOLANGIOPATHY IN COVID-19 PATIENTS: OTHER Ketamine, a nonbarbiturate general anaesthetic drug, has been proposed, off-label, as a second-line agent for maintenance sedation of patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, including those with Coronavirus infectious disease 2019 (COVID-19). 1 Cholangiopathy is reported after chronic exposure to ketamine, including in drug users and in burned NON-INVASIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. HEPATOPULMONARY SYNDROME Hepatopulmonary syndrome (HPS) is the most common cause of respiratory insufficiency in patients with chronic liver disease. It is characterised by a gas exchange abnormality caused by intrapulmonary vascular dilatations (IPVD) in patients with liver diseases. It occurs in 5–32% of liver transplant candidates.1 Abnormal oxygenation is defined by elevated alveolar-arterial oxygen gradient CIRCULAR RNA CSMARCA5 INHIBITS GROWTH AND METASTASIS IN Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.1 Although it has long been highly prevalent in Asia and Africa, it was relatively less common in the Western world. However, over the past three decades HCC incidence has doubled in the United Kingdom and tripled in the United States.2,3 Largely because of the propensity for metastasis, the five-year survival rate GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant ACUTE-ON CHRONIC LIVER FAILURE Acute-on chronic liver failure Rajiv Jalan1,⇑, Pere Gines2, Jody C Olson3, Rajeshwar P Mookerjee1, Richard Moreau4, Guadalupe Garcia-Tsao5, Vicente Arroyo2, Patrick S Kamath3 1Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, United Kingdom; 2Liver Unit, Hospital Clínic, University of Barcelona, Barcelona GASDERMIN D PLAYS A KEY ROLE AS A PYROPTOSIS EXECUTOR OF Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice Bing Xu1,y, Mingzuo Jiang1,y, Yi Chu1,y, Weijie Wang1,y, Di Chen1, Xiaowei Li1, Zhao Zhang2, Di Zhang1, Daiming Fan1, Yongzhan Nie1, Feng Shao3, Kaichun Wu1,⇑, Jie Liang1,⇑ 1State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing LOW IMMUNOGENICITY TO SARS-COV-2 VACCINATION AMONG LIVER Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk for lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity and safety in this special population. JOURNAL OF HEPATOLOGY If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password HEPATOPULMONARY SYNDROME Hepatopulmonary syndrome (HPS) is the most common cause of respiratory insufficiency in patients with chronic liver disease. It is characterised by a gas exchange abnormality caused by intrapulmonary vascular dilatations (IPVD) in patients with liver diseases. It occurs in 5–32% of liver transplant candidates.1 Abnormal oxygenation is defined by elevated alveolar-arterial oxygen gradient GLUTAMINOLYSIS-INDUCED MTORC1 ACTIVATION DRIVES NON A holistic insight on the relationship between obesity and metabolic dysfunction-associated fatty liver disease is an unmet clinical need. Omics investigations can be used to investigate the multifaceted role of altered mitochondrial pathways to promote nonalcoholic steatohepatitis, a major risk factor for liver disease-associated death. There are no specific treatments but remission via MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 GALLSTONE DISEASE: OPTIMAL TIMING OF TREATMENT Scopus (154) Google Scholar. In this Snapshot, we visualize the current treatment algorithms and discuss the optimal timing of the recommended interventions. These recommendations are based on new randomized controlled clinical trials in patients with biliary symptoms or complications. Although the genetics and pathophysiology

of gallstones

THE PARADOX OF EPSTEIN–BARR VIRUS-ASSOCIATED HEPATITIS Editorial The paradox of Epstein–Barr virus-associated hepatitis Francesco Negro* Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland ACUTE-ON CHRONIC LIVER FAILURE Acute-on chronic liver failure Rajiv Jalan1,⇑, Pere Gines2, Jody C Olson3, Rajeshwar P Mookerjee1, Richard Moreau4, Guadalupe Garcia-Tsao5, Vicente Arroyo2, Patrick S Kamath3 1Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, United Kingdom; 2Liver Unit, Hospital Clínic, University of Barcelona, Barcelona EXPANDING CONSENSUS IN PORTAL HYPERTENSION: REPORT OF THE Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for

portal hypertension

TREATMENT FAILURE WITH DAA THERAPY: IMPORTANCE OF RESISTANCE Summary Viral resistance is a major reason for virological failure in patients being treated with direct-acting an-tivirals (DAAs) for chronic HCV infection. HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity PROGRESSIVE CHOLANGIOPATHY IN COVID-19 PATIENTS: OTHER Ketamine, a nonbarbiturate general anaesthetic drug, has been proposed, off-label, as a second-line agent for maintenance sedation of patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, including those with Coronavirus infectious disease 2019 (COVID-19). 1 Cholangiopathy is reported after chronic exposure to ketamine, including in drug users and in burned A NEW DEFINITION FOR METABOLIC DYSFUNCTION-ASSOCIATED Summary The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease

(MAFLD).

NATURAL HISTORY AND PROGNOSTIC INDICATORS OF SURVIVAL IN Review Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies Gennaro D’Amico1,*, Guadalupe Garcia-Tsao2, Luigi Pagliaro1 1Gastroenterology Unit, Ospedale Cervello and University of Palermo, Italy 2Section of Digestive Diseases, Yale University and CT-VA Healthcare System, Connecticut, USA 1. Background NON-INVASIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. GLOBAL EPIDEMIOLOGY AND GENOTYPE DISTRIBUTION OF THE The treatment of chronic hepatitis C virus (HCV) infection has the potential to change significantly over the next few years as therapeutic regimens are rapidly evolving. However, the burden of chronic infection has not been quantified at the global level using the most recent data. Updated estimates of HCV prevalence, viremia and genotypes are critical for developing strategies to manage MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 HEPATITIS C VIRUS REPLICATION CYCLE Hepatitis C virus (HCV) is a positive strand RNA virus forming the genus Hepacivirus in the Flaviviridae family. Replication of HCV starts with the virus binding to hepatocytes, which are the primary, if not exclusive host cells. HCV entry is a multi-step and slow process (Panel 1). Interactions between HCV E1–E2 envelope glycoproteins and glycosaminoglycans (GAGs) contribute to primary PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant TREATMENT FAILURE WITH DAA THERAPY: IMPORTANCE OF RESISTANCE Summary Viral resistance is a major reason for virological failure in patients being treated with direct-acting an-tivirals (DAAs) for chronic HCV infection. EXPANDING CONSENSUS IN PORTAL HYPERTENSION: REPORT OF THE Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for

portal hypertension

HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity PROGRESSIVE CHOLANGIOPATHY IN COVID-19 PATIENTS: OTHER Ketamine, a nonbarbiturate general anaesthetic drug, has been proposed, off-label, as a second-line agent for maintenance sedation of patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, including those with Coronavirus infectious disease 2019 (COVID-19). 1 Cholangiopathy is reported after chronic exposure to ketamine, including in drug users and in burned A NEW DEFINITION FOR METABOLIC DYSFUNCTION-ASSOCIATED Summary The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease

(MAFLD).

NATURAL HISTORY AND PROGNOSTIC INDICATORS OF SURVIVAL IN Review Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies Gennaro D’Amico1,*, Guadalupe Garcia-Tsao2, Luigi Pagliaro1 1Gastroenterology Unit, Ospedale Cervello and University of Palermo, Italy 2Section of Digestive Diseases, Yale University and CT-VA Healthcare System, Connecticut, USA 1. Background NON-INVASIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. GLOBAL EPIDEMIOLOGY AND GENOTYPE DISTRIBUTION OF THE The treatment of chronic hepatitis C virus (HCV) infection has the potential to change significantly over the next few years as therapeutic regimens are rapidly evolving. However, the burden of chronic infection has not been quantified at the global level using the most recent data. Updated estimates of HCV prevalence, viremia and genotypes are critical for developing strategies to manage MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 HEPATITIS C VIRUS REPLICATION CYCLE Hepatitis C virus (HCV) is a positive strand RNA virus forming the genus Hepacivirus in the Flaviviridae family. Replication of HCV starts with the virus binding to hepatocytes, which are the primary, if not exclusive host cells. HCV entry is a multi-step and slow process (Panel 1). Interactions between HCV E1–E2 envelope glycoproteins and glycosaminoglycans (GAGs) contribute to primary PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant TREATMENT FAILURE WITH DAA THERAPY: IMPORTANCE OF RESISTANCE Summary Viral resistance is a major reason for virological failure in patients being treated with direct-acting an-tivirals (DAAs) for chronic HCV infection. EXPANDING CONSENSUS IN PORTAL HYPERTENSION: REPORT OF THE Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for

portal hypertension

HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaq European Association for the Study of the Liver⇑ Summary Liver cancer is the fifth most common cancer and the second PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF826 The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity PROGRESSIVE CHOLANGIOPATHY IN COVID-19 PATIENTS: OTHER Ketamine, a nonbarbiturate general anaesthetic drug, has been proposed, off-label, as a second-line agent for maintenance sedation of patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, including those with Coronavirus infectious disease 2019 (COVID-19). 1 Cholangiopathy is reported after chronic exposure to ketamine, including in drug users and in burned A NEW DEFINITION FOR METABOLIC DYSFUNCTION-ASSOCIATED Summary The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease

(MAFLD).

NATURAL HISTORY AND PROGNOSTIC INDICATORS OF SURVIVAL IN Review Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies Gennaro D’Amico1,*, Guadalupe Garcia-Tsao2, Luigi Pagliaro1 1Gastroenterology Unit, Ospedale Cervello and University of Palermo, Italy 2Section of Digestive Diseases, Yale University and CT-VA Healthcare System, Connecticut, USA 1. Background NON-INVASIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. GLOBAL EPIDEMIOLOGY AND GENOTYPE DISTRIBUTION OF THE The treatment of chronic hepatitis C virus (HCV) infection has the potential to change significantly over the next few years as therapeutic regimens are rapidly evolving. However, the burden of chronic infection has not been quantified at the global level using the most recent data. Updated estimates of HCV prevalence, viremia and genotypes are critical for developing strategies to manage MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 HEPATITIS C VIRUS REPLICATION CYCLE Hepatitis C virus (HCV) is a positive strand RNA virus forming the genus Hepacivirus in the Flaviviridae family. Replication of HCV starts with the virus binding to hepatocytes, which are the primary, if not exclusive host cells. HCV entry is a multi-step and slow process (Panel 1). Interactions between HCV E1–E2 envelope glycoproteins and glycosaminoglycans (GAGs) contribute to primary PREGNANCY AND LIVER DISEASE Pregnancy and liver disease Rachel H. Westbrook1,⇑, Geoffrey Dusheiko1, Catherine Williamson2 1The Royal Free Hospital, Sheila Sherlock Liver Centre, Pond Street, London NW3 2QG, UK; 2Division of Women’s Health, 2nd Floor, Hodgkin Building, Guy’s Campus, King’s College London, London SE1 1UL, UK Summary Pregnancy associated liver diseases affect up to 3% of pregnant TREATMENT FAILURE WITH DAA THERAPY: IMPORTANCE OF RESISTANCE Summary Viral resistance is a major reason for virological failure in patients being treated with direct-acting an-tivirals (DAAs) for chronic HCV infection. EXPANDING CONSENSUS IN PORTAL HYPERTENSION: REPORT OF THE Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for

portal hypertension

HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF the rationale behind the levels of evidence and of recommen-dations are provided (Table 1). Pathophysiology of decompensated cirrhosis The transition from compensated asymptomatic cirrhosis to HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUS EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 EASL CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF the rationale behind the levels of evidence and of recommen-dations are provided (Table 1). Pathophysiology of decompensated cirrhosis The transition from compensated asymptomatic cirrhosis to A NEW DEFINITION FOR METABOLIC DYSFUNCTION-ASSOCIATED Summary The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease

(MAFLD).

JOURNAL OF HEPATOLOGY If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password EXERCISE IN CIRRHOSIS: TRANSLATING EVIDENCE AND EXPERIENCE Physical inactivity, sarcopenia, and frailty are highly prevalent, independent predictors of morbidity and mortality in patients with cirrhosis. Across a range of chronic diseases, exercise training is a key recommendation supported by guidelines and, for some conditions, even by governmental funding of exercise programmes. Consistent with the broader chronic disease literature, the evidence GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 THE PARADOX OF EPSTEIN–BARR VIRUS-ASSOCIATED HEPATITIS Editorial The paradox of Epstein–Barr virus-associated hepatitis Francesco Negro* Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland GALLSTONE DISEASE: OPTIMAL TIMING OF TREATMENT Scopus (154) Google Scholar. In this Snapshot, we visualize the current treatment algorithms and discuss the optimal timing of the recommended interventions. These recommendations are based on new randomized controlled clinical trials in patients with biliary symptoms or complications. Although the genetics and pathophysiology

of gallstones

MANAGEMENT OF CHRONIC HEPATITIS B IN CHILDHOOD: ESPGHAN More than 360million persons worldwide (6% of the world population) are chronically infected by the hepatitis B virus (HBV). Although the incidence of HBV infection has dramatically declined since the implementation of universal immunization programs in several countries and blood-donor screening, a significant number of children are still infected each year, often developing chronic infection NEWS IN PATHOPHYSIOLOGY, DEFINITION AND CLASSIFICATION OF News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus documentq Paolo Angeli1,⇑,y, Guadalupe Garcia-Tsao2,3,y, Mitra K. Nadim4, Chirag R. Parikh5 Summary BURDEN OF LIVER DISEASES IN THE WORLD Burden of liver diseases in the world Sumeet K. Asrani1,y, Harshad Devarbhavi2,y, John Eaton3, Patrick S. Kamath3,⇑ Summary Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to compli- HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUSAASLD GUIDELINES HEPATITIS C TREATMENTHEPATITIS E TESTAASLD TREATMENT GUIDELINES HEPATITIS CAASLD HEPATITIS GUIDELINESHEPATITIS C MANAGEMENT GUIDELINESHEPATITIS C TREATMENT GUIDELINES EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a CIRCULAR RNA CSMARCA5 INHIBITS GROWTH AND METASTASIS IN Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.1 Although it has long been highly prevalent in Asia and Africa, it was relatively less common in the Western world. However, over the past three decades HCC incidence has doubled in the United Kingdom and tripled in the United States.2,3 Largely because of the propensity for metastasis, the five-year survival rate EXERCISE IN CIRRHOSIS: TRANSLATING EVIDENCE AND EXPERIENCEEXERCISE AND LIVER DISEASEEXERCISE AND LIVER HEALTHEXERCISES FOR CIRRHOSIS OF LIVERCIRRHOSIS OF THE LIVER CURABLEEND STAGE CIRRHOSIS SYMPTOMSPROGNOSIS FOR CIRRHOSIS OF LIVER Physical inactivity, sarcopenia, and frailty are highly prevalent, independent predictors of morbidity and mortality in patients with cirrhosis. Across a range of chronic diseases, exercise training is a key recommendation supported by guidelines and, for some conditions, even by governmental funding of exercise programmes. Consistent with the broader chronic disease literature, the evidence ACID-BASE DISORDERS IN LIVER DISEASE Alongside the kidneys and lungs, the liver has been recognised as an important regulator of acid-base homeostasis. While respiratory alkalosis is the most common acid-base disorder in chronic liver disease, various complex metabolic acid-base disorders may occur with liver dysfunction. While the standard variables of acid-base equilibrium, such as pH and overall base excess, often fail to HOME PAGE: JOURNAL OF HEPATOLOGYHOMESUBSCRIBEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTS In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver EASL CLINICAL PRACTICE GUIDELINES ON HEPATITIS E VIRUSAASLD GUIDELINES HEPATITIS C TREATMENTHEPATITIS E TESTAASLD TREATMENT GUIDELINES HEPATITIS CAASLD HEPATITIS GUIDELINESHEPATITIS C MANAGEMENT GUIDELINESHEPATITIS C TREATMENT GUIDELINES EASL Clinical Practice Guidelines on hepatitis E virus infectionq European Association for the Study of the Liver⇑ Summary Infection with hepatitis E virus (HEV) is a significant cause of MANAGING IMMUNE CHECKPOINT-INHIBITOR-INDUCED SEVERE Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids To the Editor: Immuno-oncology therapies are being increasingly used as a CIRCULAR RNA CSMARCA5 INHIBITS GROWTH AND METASTASIS IN Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.1 Although it has long been highly prevalent in Asia and Africa, it was relatively less common in the Western world. However, over the past three decades HCC incidence has doubled in the United Kingdom and tripled in the United States.2,3 Largely because of the propensity for metastasis, the five-year survival rate EXERCISE IN CIRRHOSIS: TRANSLATING EVIDENCE AND EXPERIENCEEXERCISE AND LIVER DISEASEEXERCISE AND LIVER HEALTHEXERCISES FOR CIRRHOSIS OF LIVERCIRRHOSIS OF THE LIVER CURABLEEND STAGE CIRRHOSIS SYMPTOMSPROGNOSIS FOR CIRRHOSIS OF LIVER Physical inactivity, sarcopenia, and frailty are highly prevalent, independent predictors of morbidity and mortality in patients with cirrhosis. Across a range of chronic diseases, exercise training is a key recommendation supported by guidelines and, for some conditions, even by governmental funding of exercise programmes. Consistent with the broader chronic disease literature, the evidence ACID-BASE DISORDERS IN LIVER DISEASE Alongside the kidneys and lungs, the liver has been recognised as an important regulator of acid-base homeostasis. While respiratory alkalosis is the most common acid-base disorder in chronic liver disease, various complex metabolic acid-base disorders may occur with liver dysfunction. While the standard variables of acid-base equilibrium, such as pH and overall base excess, often fail to JOURNAL OF HEPATOLOGY If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password GRADING AND STAGING SYSTEMS FOR INFLAMMATION AND FIBROSIS Review Grading and staging systems for inflammation and fibrosis in chronic liver diseasesq Zachary D. Goodman* Armed Forces Institute of Pathology, Department of Hepatic and Gastrointestinal Pathology and Veterans Administration Special Reference ACID-BASE DISORDERS IN LIVER DISEASE Alongside the kidneys and lungs, the liver has been recognised as an important regulator of acid-base homeostasis. While respiratory alkalosis is the most common acid-base disorder in chronic liver disease, various complex metabolic acid-base disorders may occur with liver dysfunction. While the standard variables of acid-base equilibrium, such as pH and overall base excess, often fail to A NEW DEFINITION FOR METABOLIC DYSFUNCTION-ASSOCIATED Summary The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease

(MAFLD).

MANAGEMENT OF CHRONIC HEPATITIS B IN CHILDHOOD: ESPGHAN More than 360million persons worldwide (6% of the world population) are chronically infected by the hepatitis B virus (HBV). Although the incidence of HBV infection has dramatically declined since the implementation of universal immunization programs in several countries and blood-donor screening, a significant number of children are still infected each year, often developing chronic infection MACHT – OUTPATIENT ALBUMIN INFUSIONS DO NOT PREVENT Albumin has long been an important option in the treatment of patients with cirrhosis and ascites. Albumin improves circulatory function; and is widely recommended for use in inpatients with cirrhosis complicated by hepatorenal syndrome and spontaneous bacterial peritonitis, as well as to prevent post paracentesis circulatory dysfunction following large volume paracentesis (LVP).1–4 ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITION IN CIRRHOSIS 42 was estimated as the difference between samples main- tained at 37°C and 4°C. Determination of galactose elimination capacity URSODEOXYCHOLIC ACID ‘MECHANISMS OF ACTION AND CLINICAL USE IN Review Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’q Konstantinos N. Lazaridis, Gregory J. Gores, Keith D. Lindor*,� FIBRIN(OGEN) DRIVES REPAIR AFTER ACETAMINOPHEN-INDUCED Acute liver injury caused by acetaminophen (APAP) overdose in experimental animals is associated with activation of the coagulation cascade. Strong evidence also connects APAP-induced liver injury in humans to changes in the hemostatic system including thrombocytopenia, elevated plasma levels of thrombin-antithrombin (TAT), increased levels of procoagulant microvesicles, and a reduction EASL CLINICAL PRACTICAL GUIDELINES ON THE MANAGEMENT OF EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failureq European Association for the Study of the Liver⇑ Summary The term acute liver failure (ALF) is frequently

applied as a

Hover for Description GUIDANCE FOR DESIGN AND ENDPOINTS OF CLINICAL TRIALS IN CHRONIC HEPATITIS B - REPORT FROM THE 2019 EASL-AASLD HBV TREATMENT ENDPOINTS

CONFERENCE

Hover for Description HEPATITIS A AND E COMMONALITIES AND DIFFERENCES Hover for Description Previous slide Pause slide

Next slide

* show Slide 11

* show Slide 22

* show Slide 33

* show Slide 44

* show Slide 55

* show Slide 66

* show Slide 77

Hover for Description

*

*

*

*

*

*

*

*

ARTICLES IN PRESS

*

Most Read

*

Most Cited

*

Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV

Vanwolleghem et al.

DOI: https://doi.org/10.1016/j.jhep.2020.01.024 Publication stage: In Press Journal Pre-Proof

*

A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank

Walker et al.

DOI: https://doi.org/10.1016/j.jhep.2020.01.029 Publication stage: In Press Journal Pre-Proof Published online: March 4, 2020

*

Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating the lung shunt study

Gabr et al.

DOI: https://doi.org/10.1016/j.jhep.2020.02.024 Publication stage: In Press Journal Pre-Proof Published online: March 4, 2020

*

Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study

Butt et al.

DOI: https://doi.org/10.1016/j.jhep.2020.02.022 Publication stage: In Press Journal Pre-Proof Published online: March 4, 2020

*

Portopulmonary hypertension in the current era of pulmonary hypertension management

Savale et al.

DOI: https://doi.org/10.1016/j.jhep.2020.02.021 Publication stage: In Press Journal Pre-Proof Published online: March 4, 2020 View More Articles in Press

*

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis European Association for the Study of the Liver DOI: https://doi.org/10.1016/j.jhep.2018.03.024 Journal of Hepatology, Vol. 69, Issue 2 Published online: April 10, 2018

*

Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for

portal hypertension

Roberto de Franchis on behalf of the Baveno VI Faculty DOI: https://doi.org/10.1016/j.jhep.2015.05.022 Journal of Hepatology, Vol. 63, Issue 3 Published online: June 3, 2015Open Access

*

Grading and staging systems for inflammation and fibrosis in chronic

liver diseases

Zachary D. Goodman

DOI: https://doi.org/10.1016/j.jhep.2007.07.006 Journal of Hepatology, Vol. 47, Issue 4 Published online: August 2, 2007

*

EASL Clinical Practice Guidelines: Management of hepatocellular

carcinoma

European Association for the Study of the Liver DOI: https://doi.org/10.1016/j.jhep.2018.03.019 Journal of Hepatology, Vol. 69, Issue 1 Published online: April 5, 2018

*

News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA)

consensus document

Paolo Angeli, Guadalupe Garcia-Tsao, Mitra K. Nadim, Chirag R. Parikh DOI: https://doi.org/10.1016/j.jhep.2019.07.002 Journal of Hepatology, Vol. 71, Issue 4 Published online: July 11, 2019

WebShop

------------------------- CUSTOM PRODUCTS FROM THE _JOURNAL OF HEPATOLOGY_ Want to commemorate the appearance of your article in the _Journal of Hepatology_? Follow the links to the Elsevier Webshop and order them today. Reviewer Recognition Platform -------------------------

_The Journal of

Hepatology_ participates in Elsevier's Reviewer Recognition Platform. For more information visit: http://www.reviewerrecognition.elsevier.com -------------------------

About EASL

------------------------- In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in european liver policy. For more information about EASL (http://www.easl.eu)

Current Issue

-------------------------

March 2020

Volume 72, Issue 3

* March 2020

* Volume 72, Issue 3

Past Issues

Lay Summaries

New Content Alerts

Access this journal on ScienceDirect Visit ScienceDirect to see if you have access via your institution. Update to the Guide for Authors

Snapshots

-------------------------

Dec 2019

Jul 2019

Jun 2019

May 2019

April 2019

Mar 2019

Previous slide Pause slide

Next slide

* show Slide 11

* show Slide 22

* show Slide 33

* show Slide 44

* show Slide 55

* show Slide 66

Jul 2019

Clinical Practice Guidelines ------------------------- EASL Clinical Practice Guidelines: Occupational liver diseases EASL Clinical Practice Guidelines: Drug-induced liver injury EASL Clinical Practice Guidelines on nutrition in chronic liver

disease

EASL Clinical Practice Guidelines: Management of alcohol-related liver

disease

EASL Clinical Practice Guidelines: Management of hepatocellular

carcinoma

Guidelines Collection

Journal Metrics

-------------------------

18.946

2018

Impact

Factor

2.0 weeks

Average time

from submission

to first decision

2,613,226

2018

Downloads

Supplement

------------------------- Abstract Book - The International Liver Congress™ 2019

Mobile Apps

------------------------- Download the Journal app now to read your favorite journal from anywhere in the world. As an EASL member enjoy direct access to the journal on your smart phone or tablet. Want to know how? Click here

!

Related Publication

-------------------------

_JHEP Reports_

will publish original papers, reviews, and letters to the Editor concerned with basic, translation and clinical research in the field of hepatology. Copyright © 2020 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Use of Cookies | About Us

| Help &

Contact | Accessibility The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies

.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its

manufacturer.

Loginclose

Email/Username:

Password:

Remember me

Forgot password?

Click to get updates and verify authenticity.